Xeno-oestrogens and phyto-oestrogens are alternative ligands for the androgen receptor

Asian Journal of Andrology

Volumn 12, Issue 4, 2010, Pages 535-547

  Wang, Hao ^a   Li, Jiang ^b   Gao, Yang ^a   Xu, Ying ^a   Pan, Ying ^a   Tsuji, Ichiro ^c   Sun, Zi Jie ^d   Li, Xiao Meng ^a  

^a NORTHEAST NORMAL UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

^c TOHOKU UNIVERSITY   (Japan)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

androgen receptor; dock; phyto oestrogens; xeno oestrogens

Indexed keywords

4 NONYLPHENOL; 4,4' ISOPROPYLIDENEDIPHENOL; ANDROGEN RECEPTOR; ANDROSTANOLONE; DAIDZEIN; DICHLORODIPHENYL TRICHLOROETHANE; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN; FLAVONE; GENISTEIN; THYROXINE; UNCLASSIFIED DRUG; 4-NONYLPHENOL; BENZHYDRYL DERIVATIVE; CHLORPHENOTANE; FLAVONE DERIVATIVE; ISOFLAVONE DERIVATIVE; LIGAND; PHENOL DERIVATIVE; PHYTOESTROGEN;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; HUMAN; MOLECULAR DOCKING; PREDICTION; X RAY DIFFRACTION; COMPUTER SIMULATION; METABOLISM;

BENZHYDRYL COMPOUNDS; COMPUTER SIMULATION; DDT; DIETHYLSTILBESTROL; FLAVONES; GENISTEIN; HUMANS; ISOFLAVONES; LIGANDS; PHENOLS; PHYTOESTROGENS; RECEPTORS, ANDROGEN;

EID: 77954398149     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2010.14     Document Type: Article

References (89)

1. Chang C, Kokontis J, Liao ST. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 1988; 240: 324-326
2. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 5: 276-308. (Pubitemid 38501396)
3. Rahman M, Miyamoto H, Chang C. Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications. Clin Cancer Res 2004; 10: 2208-2219 (Pubitemid 38445676)
4. Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, et al. International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev 2006; 58: 782-797
5. Roy AK, Lavrovsky Y, Song CS, Chen S, Jung MH, et al. Regulation of androgen action. Vitam Horm 1999; 55: 309-352
6. Bardin CW, Brown T, Isomaa VV, Jänne OA. Progestins can mimic, inhibit and potentiate the actions of androgens. Pharmacol Ther 1983; 23: 443-459 (Pubitemid 14145325)
7. Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs 2003; 63: 463-492 (Pubitemid 36337727)
8. Bogert CJ, Strauss MA, Harbison RD. Reproductive toxicology and occupational exposure. In: Zenz C, Dickerson OB, Horvath EP, editors. Occupational Medicine, 3rd edn. St Louis: Mosby-Year Book, Inc.; 1994. p836-69.
9. Cato AC, Nestl A, Mink S. Rapid actions of steroid receptors in cellular signaling pathways. Science's STKE 2002; 138: re9.
10. Prins GS. Endocrine disruptors and prostate cancer risk. Endocr Relat Cancer 2008; 15: 649-656
11. Clapp RW, Jacobs MM, Loechler EL. Environmental and occupational causes of cancer: new evidence 2005-2007. Rev Environ Health 2008; 23: 1-37.
12. Rumsey TS, Tyrrell HF, Dinius DA, Moe PW, Cross HR. Effect of diethylstilbestrol on tissue gain and carcass merit of feedlot beef steers. J Anim Sci 1981; 53: 589-600.
13. Calafat AM, Ye X, Wong LY, Reidy JA, Needham LL. Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003-2004. Environ Health Perspect 2008; 116: 39-44. (Pubitemid 351395596)
14. Klotz DM, Beckman BS, Hill SM, Mclachlan JA, Walters MR, et al. Identifcation of environmental chemicals with estrogenic activity using a combination of in vitro assays. Environ Health Perspect 1996; 104: 1084-1089 (Pubitemid 26395154)
15. Merrill RM, Brawley OW. Prostate cancer incidence and mortality rates among white and black men. Epidemiology 1997; 8: 126-131 (Pubitemid 27084181)
16. Ries LAG, Miller BA, Hankey BF, Kosary CL, Harras A, et al. National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Cancer Statistics Review, 1973-1991, NIH Publication No. 94-2789. Bethesda: National Cancer Institute; 1994. p1.
17. Henley DV, Korach KS. Endocrine-disrupting chemicals use distinct mechanisms of action to modulate endocrine system function. Endocrinology 2006; 147: S25-32.
18. Jian L. Soy, isoflavones, and prostate cancer. Mol Nutr Food Res 2009, 53: 217-226
19. Keri R, Ho SM, Hunt PA, Knudsen KE, Soto AM, et al. An evaluation of evidence for the carcinogenic activity of bisphenol A. Reprod Toxicol 2007; 24: 240-252 (Pubitemid 47393608)
20. Cocco P, Benichou J. Mortality from cancer of the male reproductive tract and environmental exposure to the anti-androgen p,p'- dichlorodiphenyldichloroethylene in the United States. Oncology 1998; 55: 334-339 (Pubitemid 28279675)
21. Takayama S, Sieber SM, Dalgard DW, Thorgeirsson UP, Adamson RH. Effects of long-term oral administration of DDT on nonhuman primates. J Cancer Res Clin Oncol 1999; 125: 219-225 (Pubitemid 29172514)
22. Yildiz F. Phytoestrogens in Functional Foods. Boca Raton: CRC Press Taylor &Francis Ltd; 2005. p3.
23. Adlercreutz H, Mazur W. Phyto-oestrogens and Western diseases. Ann Med 1997; 29: 95-120. (Pubitemid 27226319)
24. Messina M, Gardner C, Barnes S. Gaining insight into the health effects of soy but a long way still to go: Commentary on the fourth International Symposium on the Role of Soy in Preventing and Treating Chronic Disease. J Nutr 2002; 132: 547S-51S. (Pubitemid 34208768)
25. Denis L, Morton MS, Griffths K. Diet and its preventive role in prostatic disease. Eur Urol 1999; 35: 377-387 (Pubitemid 29229536)
26. Hwang YW, Kim SY, Jee SH, Kim YN, Nam CM. Soy food consumption and risk of prostate cancer: a meta-analysis of observational studies. Nutr Cancer 2009; 61: 598-606.
27. Sharma P, Wisniewski A, Braga-Basaria M, Xu X, Yep M, et al. Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. J Urol 2009; 182: 2265-2272
28. Eustache F, Mondon F, Canivenc-Lavier MC, Lesaffre C, Fulla Y, et al. Chronic dietary exposure to a low-dose mixture of genistein and vinclozolin modifies the reproductive axis, testis transcriptome, and fertility. Environ Health Perspect 2009; 117: 1272-1279
29. Tanaka M, Fujimoto K, Chihara Y, Torimoto K, Yoneda T, et al. Isofavone supplements stimulated the production of serum equol and decreased the serum dihydrotestosterone levels in healthy male volunteers. Prostate Cancer Prostatic Dis 2009; 12: 247-252
30. Davis JN, Kucuk O, Sarkar FH. Expression of prostate-specifc antigen is transcriptionally regulated by genistein in prostate cancer cells. Mol Carcinog 2002; 34: 91-101. (Pubitemid 34606511)
31. Rosenberg Zand RS, Jenkins DJ, Brown TJ, Diamandis EP. Flavonoids can block PSA production by breast and prostate cancer cell lines. Clin Chim Acta 2002; 317: 17-26.
32. Pendleton JM, Tan WW, Anai S, Chang M, Hou W, et al. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer 2008; 8: 132. (Pubitemid 351737018)
33. Kwan W, Duncan G, Van Patten C, Liu M, Lim J. A phase II trial of a soy beverage for subjects without clinical disease with rising prostate-specifc antigen after radical radiation for prostate cancer. Nutr Cancer 2010; 62: 198-207.
34. He YP, Hu HR, Xu LS, Meng G, Fan KN, et al. Structure-activity relationship studies on 6-naphthylmethyl substituted HEPT derivatives as non-nucleoside reverse transcriptase inhibitors based on molecular docking. Chem J Chin Univ 2005; 26: 254-258 (Pubitemid 40638523)
35. Chen HF, Gao K, Fan BT, Yuan SG, Jia ZJ, et al. Virtual screening and rational design of phenylpropanoid glycosides analogues based on molecular docking. Acta Chim Sin 2002; 60: 1860-1866 (Pubitemid 44888667)
36. Zhao LF, Ding XQ, Ding JJ, Chen JS. Homology modeling and docking studies of the α2A-adrenergic receptor. Acta Phys Chim Sin 2005; 21: 151-155 (Pubitemid 40228631)
37. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, effcient optimization and multithreading. J Comput Chem 2010; 31: 455-461
38. Pereira de Jésus-Tran K, Côté PL, Cantin L, Blanchet J, Labrie F, et al. Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affnity. Protein Sci 2006; 15: 987-999
39. Lill MA, Winiger F, Vedani A, Ernst B. Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals. J Med Chem 2005; 48: 5666-5674 (Pubitemid 41298341)
40. D'Ursi P, Salvi E, Fossa P, Milanesi L, Rovida E. Modelling the interaction of steroid receptors with endocrine disrupting chemicals. BMC Bioinformatics 2005; 6 Suppl 4: S10. (Pubitemid 46437522)
41. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389: 753-758 (Pubitemid 27458965)
42. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, et al. Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J Comp Chem 1998; 19: 1639-1662 (Pubitemid 128590223)
43. Lee HJ, Chattopadhyay S, Gong EY, Ahn RS, Lee K. Antiandrogenic effects of bisphenol A and nonylphenol on the function of androgen receptor. Toxicol Sci 2003; 75: 40-46 (Pubitemid 37098734)
44. Montgomery RB, Nelson PS, Lin D, Ryan CW, Garzotto M, et al. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer. Cancer 2007; 110: 996-1002. (Pubitemid 47312864)
45. Takezawa Y, Nakata S, Kobayashi M, Kosaku N, Fukabori Y, et al. Moderate dose diethylstilbestrol diphosphate therapy in hormone refractory prostate cancer. Scand J Urol Nephrol 2001; 35: 283-287 (Pubitemid 32906849)
46. Wetherill YB, Hess-Wilson JK, Comstock CE, Shah SA, Buncher CR, et al. Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer. Mol Cancer Ther 2006; 5: 3181-3190 (Pubitemid 46092061)
47. Chen JJ, Chang HC. By modulating androgen receptor coactivators, daidzein may act as a phytoandrogen. Prostate 2007; 67: 457-462
48. Gao S, Liu GZ, Wang Z. Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells. Prostate 2004; 59: 214-225 (Pubitemid 38481232)
49. Cocco P. On the rumors about the silent spring. Review of the scientific evidence linking occupational and environmental pesticide exposure to endocrine disruption health effects. Cad Saude Publica 2002; 18: 379-402.
50. Inaguma S, Takahashi S, Imaida K, Suzuki S, Shirai T. p-Nonylphenol pretreatment during the late neonatal period has no effect on 3,2′-dimethyl-4-aminobiphenyl-induced prostate carcinogenesis in male F344 rats. Cancer Lett 2004; 212: 159-166 (Pubitemid 38997972)
51. Yoshino H, Nabae K, Doi Y, Ichihara T, Tamano S. Lack of effects of gestational and lactational exposure to 4-nonylphenol on PhIP-induced rat prostate carcinogenesis. Toxicol Pathol 2005; 18: 183-188 (Pubitemid 43103808)
52. Timms BG, Howdeshell KL, Barton L, Bradley S, Richter CA, et al. Estrogenic chemicals in plastic and oral contraceptives disrupt development of the fetal mouse prostate and urethra. Proc Natl Acad Sci USA 2005; 102: 7014-7019 (Pubitemid 40675432)
53. Ho SM, Tang W Y, Belmonte de Frausto J, Prins GS. Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. Cancer Res 2006; 66: 5624-5632 (Pubitemid 43927114)
54. Murray TJ, Maffini M V, Ucci AA, Sonnenschein C, Soto AM. Induction of mammary gland ductal hyperplasias and carcinoma in situ following fetal bisphenol A exposure. Reprod Toxicol 2007; 23: 383-390 (Pubitemid 46602926)
55. Wetherill YB, Petre CE, Monk KR, Puga A, Knudsen KE. The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells. Mol Cancer Ther 2002; 1: 515-524
56. Wetherill YB, Fisher NL, Staubach A, Danielsen M, de Vere White RW, et al. Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status. Cancer Res 2005; 65: 54-65. (Pubitemid 40070795)
57. Serrate C, Loriot Y, De La Motte Rouge T, Gross-Goupil M, Massard C, et al. Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer. Ann Oncol 2009; 20: 965.
58. Scherr D, Pitts WR Jr, Vaughn ED Jr. Diethylstilbesterol revisited: androgen deprivation, osteoporosis and prostate cancer. J Urol 2002; 167: 535-538 (Pubitemid 34074522)
59. Malkowicz SB. The role of diethylstilbestrol in the treatment of prostate cancer. Urology 2001; 58: 108-113 (Pubitemid 32743424)
60. Kurahashi N, Iwasaki M, Sasazuki S, Otani T, Inoue M, et al. Soy product and isofavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol Biomarkers Prev 2007; 16: 538-545 (Pubitemid 46548658)
61. Allen NE, Sauvaget C, Roddam AW, Appleby P, Nagano J, et al. A prospective study of diet and prostate cancer in Japanese men. Cancer Causes Control 2004; 15: 911-920 (Pubitemid 39663867)
62. Nomura AM, Hankin JH, Lee J, Stemmermann GN. Cohort study of tofu intake and prostate cancer: no apparent association. Cancer Epidemiol Biomarkers Prev 2004; 13: 2277-2279 (Pubitemid 40054330)
63. Jacobsen BK, Knutsen SF, Fraser GE. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control 1998; 9: 553-557
64. Severson RK, Nomura AM, Grove JS, Stemmermann GN. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res 1989; 49: 1857-1860
65. Li X, Li J, Tsuji I, Nakaya N, Nishino Y, et al. Mass screening-based case-control study of diet and prostate cancer in Changchun, China. Asian J Androl 2008; 10: 551-560 (Pubitemid 351865761)
66. Nagata Y, Sonoda T, Mori M, Miyanaga N, Okumura K, et al. Dietary isofavones may protect against prostate cancer in Japanese men. J Nutr 2007; 137: 1974-1979 (Pubitemid 47292748)
67. Sonoda T, Nagata Y, Mori M, Miyanaga N, Takashima N, et al. A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet. Cancer Sci 2004; 95: 238-242 (Pubitemid 38489090)
68. Lee MM, Gomez SL, Chang JS, Wey M, Wang RT, et al. Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev 2003; 12: 665-668 (Pubitemid 36899850)
69. Kolonel LN, Hankin JH, Whittemore AS, Wu AH, Gallagher RP, et al. Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomarkers Prev 2000; 9: 795-804.
70. Jain MG, Hislop GT, Howe GR, Ghadirian P. Plant foods, antioxidants, and prostate cancer risk: fndings from case-control studies in Canada. Nutr Cancer 1999; 34: 173-184
71. Strom SS, Yamamura Y, Duphorne CM, Spitz MR, Babaian RJ, et al. Phytoestrogen intake and prostate cancer: a case-control study using a new database. Nutr Cancer 1999; 33: 20-25 (Pubitemid 29196118)
72. Villeneuve PJ, Johnson KC, Kreiger N, Mao Y. Risk factors for prostate cancer: results from the Canadian National Enhanced Cancer Surveillance System. The Canadian Cancer Registries Epidemiology Research Group. Cancer Causes Control 1999; 10: 355-367 (Pubitemid 29454312)
73. El Touny LH, Banerjee PP. Identifcation of a biphasic role for genistein in the regulation of prostate cancer growth and metastasis. Cancer Res 2009; 69: 3695-3703
74. Wang J, Eltoum IE, Lamartiniere CA. Genistein chemopre-vention of prostate cancer in TRAMP mice. J Carcinog 2007; 6: 3. (Pubitemid 46502381)
75. Zhou JR, Gugger ET, Tanaka T, Guo Y, Blackburn GL, et al. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr 1999; 129: 1628-1635 (Pubitemid 29406613)
76. Bemis DL, Capodice JL, Desai M, Buttyan R, Katz AE. A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo. Clin Cancer Res 2004; 10: 5282-5292 (Pubitemid 39099803)
77. Zhou JR, Yu L, Zhong Y, Blackburn GL. Soy phytochem-icals and tea bioactive components synergistically inhibit androgen-sensitive human prostate tumors in mice. J Nutr 2003; 133: 516-521 (Pubitemid 36172909)
78. Kohen F, Gayer B, Kulik T, Frydman V, Nevo N, et al. Synthesis and evaluation of the antiproliferative activities of derivatives of carboxyalkyl isofavones linked to N-t-Boc-hexylenediamine. J Med Chem 2007; 50: 6405-6410 (Pubitemid 350250427)
79. Shukla S, MacLennan GT, Flask CA, Fu P, Mishra A, et al. Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice. Cancer Res 2007; 67: 6925-6935 (Pubitemid 47105540)
80. Singh RP, Agrawal P, Yim D, Agarwal C, Agarwal R. Acacetin inhibits cell growth and cell cycle progression, and induces apoptosis in human prostate cancer cells: structure-activity relationship with linarin and linarin acetate. Carcinogenesis 2005; 26: 845-854 (Pubitemid 41214348)
81. Drees M, Dengler WA, Roth T, Labonte H, Mayo J, et al. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res 1997; 3: 273-279 (Pubitemid 27107305)
82. Akaza H, Miyanaga N, Takashima N, Naito S, Hirao Y, et al. Is daidzein non-metabolizer a high risk for prostate cancer? A case-controlled study of serum soybean isofavone concentration. Jpn J Clin Oncol 2002; 32: 296-300. (Pubitemid 43102798)
83. Rogan WJ, Chen A. Health risks and benefits of bis(4-chlorophenyl)-1,1,1- trichloroethane (DDT). Lancet 2005; 366: 763-773 (Pubitemid 41207240)
84. Eskenazi B, Chevrier J, Rosas LG, Anderson HA, Born-man MS, et al. The Pine River Statement: human health consequences of DDT use. Environ Health Perspect 2009; 117: 1359-1367
85. Kao PC, P'Eng FK. How to reduce the risk factors of osteoporosis in Asia. Zhonghua Yi Xue Za Zhi (Taipei) 1995; 55: 209-213
86. Travis RC, Spencer EA, Allen NE, Appleby PN, Roddam AW, et al. Plasma phyto-oestrogens and prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 2009; 100: 1817-1823
87. Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 1993; 342: 1209-1210 (Pubitemid 23331713)
88. Li X, Tsuji I, Kuwahara M, Zhang H, Wang H, et al. Mass screening of prostate cancer in Changchun City of China. Int Urol Nephrol 2004; 36: 541-548 (Pubitemid 40208033)
89. Kuwahara M, Tochigi T, Kawamura S, Ogata Y, Xu N, et al. Mass screening for prostate cancer: a comparative study in Natori, Japan and Changchun,China. Urology 2003; 61: 137-141 (Pubitemid 36151729)